39796-52-6

Basic information

• Product Name: 2-amino-N-benzylacetamide
• Synonyms: 2-amino-N-benzylacetamide
• CAS NO: 39796-52-6
• Molecular Formula: C₉H₁₂N₂O
• Molecular Weight: 164.20438
• Mol File: 39796-52-6.mol
• Article Data: 21

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C(protect from light)
• CAS DataBase Reference: 2-amino-N-benzylacetamide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-amino-N-benzylacetamide(39796-52-6)
• EPA Substance Registry System: 2-amino-N-benzylacetamide(39796-52-6)

Safety Data

• Hazardous Substances Data: 39796-52-6(Hazardous Substances Data)

Usage

Molecular weight

191.23 g/mol
Derivative of acetamide
Consists of a benzyl group attached to the nitrogen atom of an amino group
Potential biological activity
Studied for potential use in the treatment of various medical conditions, including cancer
Interest for further research and development in the field of pharmaceuticals

Upstream product

• 4905-17-3 N-benzyl-2-(1,3-dioxo-1,3-dihydroisoindol-2-yl)acetamide 
• 616-34-2 methoxycarbonylmethylamine 
• 100-46-9 benzylamine 
• 5680-79-5 glycine ethyl ester hydrochloride 
• 623-33-6 glycine ethyl ester hydrochloride 
• 2185-00-4 1,3-oxazolidine-2,5-dione 
• 14856-79-2 N-benzyl(trimethylsilyl)amine 
• 2642-32-2 benzyl (2-(benzylamino)-2-oxoethyl)carbamate 
• 17038-67-4 N²-<4-Oxo-penten-(2)-yl-(2)>-α-amino-essigsaeure-benzylamid 
• 17038-68-5 N²-<2-Benzoyl-vinyl>-α-amino-essigsaeure-benzylamid 
• 459-73-4 GlyOEt*HCl 
• 6000-43-7 2-aminoethanoic acid hydrochloride 
• 56-40-6 glycine 
• 2945-03-1 N-benzyl-2-bromoacetamide 

Downstream Products

• 18895-30-2 N-(2-Hydroxy-naphthyl-⁽¹⁾-methylen)-glycin-(N-benzyl-amid) 
• 937396-37-7 3-benzyl-2,2-dimethylimidazolidin-4-one 
• 885022-88-8 C₂₄H₂₂F₃N₅O₄ 
• 1438895-38-5 C₁₅H₂₀N₂O 
• 1438895-37-4 C₁₅H₁₇ClN₂O 
• 1438895-17-0 C₁₇H₁₇N₃O 
• 1438895-18-1 C₁₇H₁₇N₃O 
• 1438895-19-2 1-benzyl-3-phenyl-1,4-diazaspiro[4.5]dec-3-en-2-one 
• 1438895-20-5 C₂₁H₂₁FN₂O 
• 1438895-21-6 C₂₁H₂₁FN₂O 
• 1438895-22-7 C₂₁H₂₁FN₂O 
• 1438895-23-8 C₂₁H₂₀F₂N₂O 
• 1438895-24-9 C₂₂H₂₄N₂O 
• 1438895-25-0 C₂₂H₂₄N₂O 

Relevant articles and documents

KINASE INHIBITOR

The present invention aims to provide a novel kinase inhibitor and the like, and a therapeutic agent for a disease, a drug discovery screening method and the like utilizing such inhibitor and the like. The compound represented by the following formula (I) and a salt thereof can inhibit plural kinases including LATS (particularly LATS2) which is the major kinase in the Hippo signal transduction pathway. In addition, diseases or tissue damage associated with failure of cellular proliferation can be treated. Therefore, the present invention is beneficial, for example, in the research field of cell functions and diseases, in which the Hippo signal transduction pathway is involved, and the like. Furthermore, it is beneficial in the medical field for the treatment of such diseases and the like. wherein each symbol is as defined in the DESCRIPTION.

Protecting-Group-Free Amidation of Amino Acids using Lewis Acid Catalysts

Amidation of unprotected amino acids has been investigated using a variety of ‘classical“ coupling reagents, stoichiometric or catalytic group(IV) metal salts, and boron Lewis acids. The scope of the reaction was explored through the attempted synthesis of amides derived from twenty natural, and several unnatural, amino acids, as well as a wide selection of primary and secondary amines. The study also examines the synthesis of medicinally relevant compounds, and the scalability of this direct amidation approach. Finally, we provide insight into the chemoselectivity observed in these reactions.

Synthesis and antitumor activities of chiral dipeptide thioureas containing an alpha-aminophosphonate moiety

Thiourea derivatives demonstrate potent cytotoxic activity against various leukemias and many tumor cell lines. In our previous study, the combination of thiourea and phosphonate has been proven as an effective strategy for developing antitumor agents. Herein, we synthesized and evaluated a series of novel chiral dipeptide thioureas containing an α-aminophosphonate moiety as antitumor agents. Finally, we developed novel dipeptide thioureas 11d and 11f that showed comparable inhibition with that of Cisplatin against BGC-823 and A-549 cells, respectively.